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Abstract
Rationale Many older adults report sleep problems and use of
hypnotics. Several studies have shown that hypnotics can
have acute adverse effects on driving the next morning. It is
unclear however whether driving of chronic hypnotic users is
impaired. Therapeutic effects on insomnia and development
of tolerance may reduce the residual effects on driving.
Objectives The present study aimed to compare actual driving
performance and driving-related skills of chronic hypnotic
users to good sleepers. To determine whether insomnia itself
affects driving performance, driving and driving-related skills
were compared between insomnia patients who do not or
infrequently use hypnotics and good sleepers.
Methods Twenty-two frequent users of hypnotics (using hyp-
notics ≥4 nights per week for more than 3 months), 20 infre-
quent users (using hypnotics ≤3 nights per week), and 21
healthy, age-matched controls participated in this study. On
the night before testing, all subjects were hospitalized for an
8-h sleep recorded by polysomnography. Frequent hypnotic
users used their regular medication at bedtime (2330 hours),
while infrequent users and controls received no medication.
Cognitive performance (word learning, digit span, tracking,
divided attention, vigilance, and inhibitory control) was
assessed 8.5 h and driving performance between 10 and 11 h
after bedtime and dosing.
Results Polysomnographic recordings did not significantly
differ between the groups, but the insomnia patients, treated
or untreated, still reported subjective sleep complaints. Results
show no differences in driving performance and driving-
related skills between both groups of insomnia patients and
controls.
Conclusions Driving performance in chronic users of hyp-
notics and untreated insomnia patients is not impaired. For
chronic users, this may be due to prescription of relatively safe
drugs and low doses. For untreated insomniacs, this corrobo-
rates previous findings showing an absence of neuropsycho-
logical deficits in this group of patients.
Keywords On-the-road driving . Insomnia . Hypnotics .
Cognition . Elderly
Introduction
Approximately one third of the general adult population suffers
from insomnia, reporting difficulties in initiating sleep or in
maintaining sleep, and feelings of nonrestorative sleep
(Ohayon 2002; Morin et al. 2006). Although non-
pharmacological strategies, such as cognitive behavioral therapy,
are increasingly being implemented in the treatment of insomnia,
pharmacotherapy is still the most frequently used treatment
(Morin et al. 2007). The primary choice of sleep-enhancing
medication is sedative hypnotics, such as benzodiazepines and
the newer benzodiazepine receptor agonists zopiclone,
zolpidem, and zaleplon (Verster et al. 2007; Lader 2011).
Ideally, a hypnotic should improve sleep, but be free from
residual sedative effects after arising. It is known, however,
that a number of hypnotics that are currently prescribed can
produce next-day residual sedation, depending on type of
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hypnotic, dose, time after administration, and frequency of
dosing (Vermeeren 2004). This may lead to impairment of a
wide range of cognitive abilities and can have serious conse-
quences for daily activities, such as driving a car. In epidemi-
ological studies, for example, it has been shown that use of
hypnotics is related to an increased risk of becoming involved
in traffic and occupational accidents (Ray et al. 1992;
Hemmelgarn et al. 1997; Barbone et al. 1998; Neutel 1998;
Dubois et al. 2008; Dassanayake et al. 2011). Experimental
studies assessing actual driving performance after administra-
tion of hypnotics confirm these data by showing residual
driving impairment in the morning after dosing (Volkerts
and O’Hanlon 1988; Vermeeren 1995; Vermeeren et al.
1998, 2002; Verster et al. 2002; Leufkens et al. 2009).
In order to select the safest alternative among the available
hypnotics, patients and prescribing physicians should be in-
formed about the possible impairing effects of hypnotics. To
date, information of the residual effects on driving perfor-
mance is mainly derived from experimental studies conducted
with young, healthy, hypnotic-naïve volunteers after a single
night of treatment. Investigating the residual effects in this
population leaves two important issues unanswered. First, it
may be possible that the effects of hypnotics interact with
insomnia in such a way that they are experienced differently
between insomniacs and healthy, young volunteers. Secondly,
the majority of insomniacs use hypnotics chronically, which
may induce tolerance to their residual effects. As a conse-
quence, the impairing effects may be less pronounced in
insomniacs than in healthy volunteers.
Untreated insomniacs report reduced performance in daily
life routines, which may have serious detrimental conse-
quences (Chambers and Keller 1993; Varkevisser and
Kerkhof 2005; Sarsours et al. 2011; Roth et al. 2011). It can,
therefore, be expected that daytime performance after
hypnotic-induced sleep is improved in insomniacs. Healthy
volunteers, on the other hand, cannot benefit from hypnotic
treatment as their performance is already optimal. Impairment
observed due to hypnotic sedation in healthy volunteers may
therefore be an overestimation of the net effects of hypnotics
in patients. However, most experimental studies examining
cognitive and psychomotor performance showed that daytime
functioning in untreated insomnia patients was not (Riedel
and Lichstein 2000; Fulda and Schulz 2001) or only minimal-
ly impaired (Shekleton et al. 2010; Bastien 2011; Fortier-
Brochu et al. 2012).
Whereas experimental studies have failed to demonstrate
impaired daytime functioning, it has been shown in a cross-
sectional epidemiological study that difficulties in sleeping are
associated with an increased risk in occupational fatal acci-
dents (Akerstedt et al. 2002). More recently, in a study inves-
tigating the relationship between health-related complaints
and crash involvement risk, it was found that sleep distur-
bances were associated with an elevated risk of becoming
involved in car accidents (Sagberg 2006). The differences in
findings of experimental and epidemiological research may be
explained by possible limitations related to the type of re-
search. Epidemiological studies may not have been able to
control for other factors contributing to impaired daytime
functioning. For example, insomnia is strongly associated
with disorders such as depression and anxiety (Stewart et al.
2006). These disorders have been shown to affect daily func-
tions as well (Kindermann and Brown 1997; Kizilbash et al.
2002; Wingen et al. 2006) and may have influenced the
results. The absence of objective impairment in experimental
studies is mainly explained by a lack of laboratory tests
demanding high effort (Vignola et al. 2000; Altena et al.
2008; Edinger et al. 2008). Most performance tasks are of
short duration and insomniacs may relatively easy be able to
maintain high-level performance during testing (Varkevisser
and Kerkhof 2005).
The second issue that has not yet been clarified in experi-
mental designs using healthy young volunteers is whether
residual effects of hypnotics are still present in insomniacs
who chronically use hypnotics. Although it is not recommend-
ed to use hypnotics for periods longer than 4 weeks, a majority
of insomnia patients are treated for prolonged periods (Ashton
2005; Paterniti et al. 2002). This may induce the development
of tolerance to the residual effects of hypnotics (Bateson
2002). The impairing effects in hypnotic-naïve volunteers
might therefore be larger than the actual effects on perfor-
mance of insomniacs chronically using hypnotics. For exam-
ple, a recent experimental study demonstrated that perfor-
mance of chronic users of hypnotics was comparable to that
of untreated insomnia patients and self-defined good sleepers
(Vignola et al. 2000).
In summary, it is unclear whether driving performance of
chronic users of hypnotics is impaired. The primary objective
of the present study was therefore to compare actual driving
performance and driving-related skills of chronic users of
hypnotics to good sleepers. In case no difference in perfor-
mance is found between these groups, this might be due to
tolerance to the adverse effects of hypnotics, or the therapeutic
effects of hypnotics on insomnia and performance, or both. To
determine whether insomnia itself has adverse effects on
driving performance, the secondary objective was to compare
driving and driving-related skills between insomnia patients
who do not or infrequently use hypnotics and good sleepers.
Methods
Subjects
A total of 42 insomnia patients and 21 healthy controls were
recruited through a network of local general practitioners in
the region of Maastricht, The Netherlands (Regionaal
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Netwerk Huisartsen), and by advertisement in local newspa-
pers. All participants had to meet the following inclusion
criteria: aged between 50 and 75 years; possession of a valid
driving license for at least 3 years; average driving experience
of at least 3,000 km per year over the last 3 years; good health
based on a pre-study physical examination, medical history,
vital signs, electrocardiogram, blood biochemistry, hematolo-
gy, serology, and urinalysis. Exclusion criteria were history of
drug or alcohol abuse; presence of a significant medical,
neurological, psychiatric disorder, or sleep disorder other than
insomnia; chronic use of medication that affects driving per-
formance, except hypnotics; drinking more than 6 cups of
coffee per day; drinking more than 21 units of alcohol per
week; smoking more than 10 cigarettes per day; and body
mass index outside the range of 19 to 30 kg/m2.
Insomnia patients had to meet the inclusion criteria for
primary insomnia according to DSM-IV (American
Psychiatric Association 1994): (1) subjective complaints of
insomnia, defined as difficulties initiating sleep (sleep latency
>30 min) and/or maintaining sleep (awakenings >30 min); (2)
duration of more than 1 month; (3) the sleep disturbance
causes clinically significant distress or impairment; (4) insom-
nia does not occur exclusively during the course of a mental
disorder; and (5) insomnia is not due to another medical or
sleep disorder or effects of medication or drug abuse.
Volunteers were screened by a telephone interview, ques-
tionnaires, and a physical examination. Insomnia patients’
sleep complaints were evaluated by a trained psychologist
using Dutch versions of the Pittsburgh Sleep Quality Index
(PSQI) (Buysse et al. 1989), the Sleep Wake Experience List
(SWEL) (van Diest et al. 1989), and the Groningen Sleep
Quality Scale (GSQS) (Mulder-Hajonides van der Meulen
1981). The GSQS provides a score between 0 and 14
representing a number of sleep complaints. In addition, sub-
jects completed a sleep log for 14 days, providing daily
information about estimated sleep and wake times, and sleep
quality using the GSQS (Mulder-Hajonides van der Meulen
1981). Major psychopathology was screened using the
Symptom Checklist 90 Revised (SCL90-R) (Derogatis
1983), the Beck Depression Inventory (BDI) (Beck et al.
1961), the State-Trait Anxiety Inventory (STAI) (Spielberger
et al. 1983), and the Multidimensional Fatigue Inventory
(Smets et al. 1995).
Insomnia patients were assigned to one of two groups
depending on the frequency and duration of their use of
hypnotic drugs (benzodiazepine, zopiclone, or zolpidem).
Patients were assigned to a “frequent users” group when they
used a hypnotic for at least four nights per week and longer
than 3 months (n = 22). Patients not using hypnotics or using
hypnotics less than or equal to 3 days per week were assigned
to the “infrequent users” group (n = 20).
The study was conducted in accordance with the code of
ethics on human experimentation established by the World
Medical Association’s Declaration of Helsinki (1964) and
amended in Edinburgh (2000). The protocol was approved
by the medical ethics committee of Maastricht University and
University Hospital of Maastricht. Subjects were explained
the aims, methods, and potential hazards of the study and they




Driving performance was assessed using two standardized
driving tests developed to measure different aspects of driving
performance. The primary test is the Highway Driving Test
(O’Hanlon 1984) which measures road tracking performance.
Performance in this test is mainly determined by the delay lag
between sensory information, execution of motor reaction,
and the vehicle’s dynamic response. In this test, subjects
operate a specially instrumented vehicle over a 100-km (61-
mi) primary highway circuit, accompanied by a licensed driv-
ing instructor having access to dual controls. The subjects’
task is to maintain a constant speed of 95 km/h (58 mi/h) and a
steady lateral position between the delineated boundaries of
the slower traffic lane. The vehicle speed and lateral position
are continuously recorded. These signals are edited offline to
remove data recorded during overtaking maneuvers or distur-
bances caused by roadway or traffic situations. The remaining
data are then used to calculate means and standard deviations
of lateral position and speed. Standard deviation of lateral
position (SDLP in centimeters) is the primary outcome vari-
able. SDLP is a measure of road tracking error or “weaving.”
The test duration is approximately 1 h.
SDLP is an extremely reliable index of individual driving
performance and has proven sensitive to many sedating drugs
(O’Hanlon and Ramaekers 1995; O’Hanlon et al. 1995;
Ramaekers 2003; Vermeeren 2004; Verster 2004). Test–retest
reliability ranges between 0.7 and 0.9 in individual studies and
is on average 0.85. The test was calibrated for the effects of
alcohol in a closed circuit study wherein 24 social drinkers
were tested sober and after controlled drinking to raise blood
alcohol concentrations in steps of 0.3 g/L to a maximum of
1.2 g/L (Louwerens et al. 1987). In line with the relationship
between blood alcohol concentration (BAC) and accident risk
as estimated in a large epidemiological study by Borkenstein
(1974), the relationship between BAC and SDLP was shown
to be an exponential function. Based on this relationship,
BACs of 0.5, 0.8, and 1.0 g/L were associated with mean
changes in SDLP of 2.4, 4.2, and 5.1 cm, respectively. The
increase in SDLP caused by 0.5 g/L alcohol is considered
clinically meaningful since accident risk has been demonstrat-
ed to increase significantly above this BAC in large epidemi-
ological studies (Borkenstein 1974; Krüger et al. 1994). The
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average SDLP score of 219 healthy volunteers was 18.2 cm
(SD = 3.1 cm) after placebo treatments in various recent
studies (data on file). Based on these data, sample sizes of
20 subjects per group ensure 80 % power to detect a clinically
meaningful difference between groups (with an alpha level of
0.05) in the primary variable of this study, SDLP.
The Car-Following Test (Brookhuis et al. 1994; Ramaekers
and O’Hanlon 1994) measures changes in controlled informa-
tion processing such as selective attention, stimulus interpre-
tation and decision making, and speed of an adaptive motor
response to events which are common in driving. In the test,
two vehicles travel in tandem over a two-lane, undivided,
secondary highway at 70 km/h (44 mi/h). An investigator
drives the leading car and the subject, in the second car, is
instructed to follow at a distance between 25 and 35 m.
Subjects are further instructed to constantly attend the leading
car since it may slow down or speed up at unpredictable times.
They are required to follow the leading car’s speed move-
ments, i.e., maintain the initial headway by matching the
velocity of the car to the other’s. During the test, the speed
of the leading car is automatically controlled by a modified
“cruise control” system. At the beginning, it is set to maintain
a constant speed of 70 km/h and, by activating a micropro-
cessor, the investigator can start sinusoidal speed changes
reaching amplitude of −10 km/h and returning to the starting
level within 50 s. The maneuver is repeated six times. The
leading car’s speed and signals indicating the beginning of the
maneuver are transmitted via telemetry to be recorded in the
following vehicle together with the following vehicle’s speed.
Phase-delay converted to a measure of the subject’s average
reaction time to the movement of the leading vehicle (RT, in
second) is taken as the primary dependent variable in this test.
A secondary measure in the Car-Following Test is Gain. It
represents an amplification factor between the signals of the
two cars. This will be larger than 1 when the subject overreacts
to speed adaptations of the leading car. Test duration is 25 min.
Cognitive and psychomotor performance
Cognitive and psychomotor performance was assessed by
tests for word learning, digit span, tracking, divided attention,
sustained attention, and inhibitory control. Tests were selected
based on their sensitivity to residual sedating effects of hyp-
notics or sleep disturbances, and their relationship to driving
performance (Vermeeren 1995; Vermeeren et al. 1998, 2002;
Fulda and Schulz 2001; Verster et al. 2002; Vermeeren 2004;
Leufkens et al. 2009; Leufkens and Vermeeren 2009).
The Word Learning Test (Rey 1964) is a verbal memory
test for the assessment of immediate recall, delayed recall, and
recognition performance. Fifteen monosyllabic nouns are pre-
sented, and at the end of the sequence, the subject is asked to
recall as many words as possible. This procedure is repeated
five times, and after a delay of at least 30 min, the subject is
again required to recall as many words as possible. At this
trial, the nouns are not presented. Finally, a sequence of 30
monosyllabic nouns is presented, containing 15 nouns from
the original set and 15 new nouns in random order. The
subject has to indicate whether a noun originates from the
old set or it is from a new set of nouns. The main performance
parameters are Immediate Total Recall Score (number of
immediately correctly recalled words), Delayed Recall Score
(number of correctly recalled words after a 30-min delay),
Recognition Score (number of correctly recognized words),
and Recognition Response Time (in millisecond).
The Digit Span Forward and Backward is a subtest of the
Wechsler Adult Intelligence Scale-Revised and measures the
storage capacity of an individual’s working memory
(Wechsler 1981). In this test, subjects are asked to repeat
orally presented digits with increasing sequence length, either
in forward or reverse order. There are two trials at each series
length, and the test continues until both trials of a series length
are failed. One point is awarded for each correct trial resulting
in a Digit Span Forward Score and a Digit Span Backward
Score.
The Critical Tracking Test (Jex et al. 1966) measures the
ability to control an unstable signal in a tracking task. The
signal deviates horizontally from a midpoint with increasing
velocity and the subject has to compensate this signal devia-
tion by moving a joystick in opposite direction. The velocity
(lambda in radian/second) at which the subject loses control is
measured. The test includes five trials of which the lowest and
the highest score are discarded. The performance parameter is
the average lambda (radian/second) of the remaining three
scores, reflecting the critical tracking velocity.
The Divided Attention Task (Moskowitz 1973) measures
the ability to divide attention between two simultaneously
performed tasks. The first task is to perform the tracking test
at a fixed level of difficulty, with velocity set at 50 % of the
maximum score obtained after extensive training of the
Critical Tracking Test. In the other task, the subject has to
monitor 24 single digits that are presented in the four corners
of the screen. The digits change asynchronously at 5-s inter-
vals. The subjects are instructed to remove their foot from a
pedal as rapidly as possible whenever the digit “2” appears.
This signal occurs twice at every location, in random order, at
intervals of 5 to 25 s.
In the Stop Signal Task (Logan et al. 1984), the concept of
inhibitory control is defined as the ability to stop a pending
thought or action and to begin another. The paradigm consists
of two concurrent tasks, i.e., a go task (primary task) and a
stop task (secondary task). The go signals (primary task stim-
uli) are two letters (“X” or “O”) presented one at a time in the
center of a computer screen. Subjects are required to respond
to each letter as quickly as possible by pressing on of two
response buttons. Occasionally, a stop signal (secondary task
stimulus) occurs during the test. Subjects are required to
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withhold any response in case a stop signal is presented. The
stop signal consists of an auditory cue, i.e., a 1,000-Hz tone,
that is presented for 100 ms. The interval at which the stop
signal is presented is dependent from the subject’s own suc-
cessful and unsuccessful inhibitions. By continuously moni-
toring the subject’s response, the Stop Signal Delay is adjusted
producing the probability of responding [p(respond|signal)]
equal to 0.50. Consequently, the stop signal reaction time is
estimated by determining the mean of the inhibition function,
which is then subtracted from the mean go RT. Task duration
is 14 min.
The Psychomotor Vigilance Task (Dinges and Powell
1985) is based on a simple visual RT test. Subjects are re-
quired to respond to a visual stimulus presented at variable
interval (2,000 to 10,000 ms) by pressing a button with the
dominant hand. The visual stimulus is a counter turning on
and incrementing from 0 to 60 s at 1-ms intervals. In response
to the subject’s button press, the counter display stops
incrementing, allowing the subject 1 s to read the RT before
the counter restarts. If a response has not been made in 60 s,
the clock resets and the counter restarts. The median reaction
time and the number of lapses (i.e., response times >500 ms)
were used as the main performance parameters. The test
duration is 10 min.
Polysomnography
On nights before testing, sleep quality and duration were
measured by polysomnography usingmontage including elec-
troencephalogram, electrooculogram, and electromyogram.
Sleep stages were visually assessed by experienced techni-
cians according to standardized criteria (Iber et al. 2007).
Technicians were only informed about the age and sex of the
subjects, but were blinded to the group affiliation of the
subjects. Parameters derived after analysis are sleep onset
latency (in minute), wake after sleep onset (in minute), total
sleep time (in minute), sleep efficiency (in percent), and
number of awakenings.
Subjective evaluations
Upon arising, subjects completed the specific version of the
Groningen Subjective Quality of Sleep questionnaire (GSQS)
(Mulder-Hajonides van der Meulen 1981), providing a score
between 0 and 14 representing a number of sleep complaints.
In addition, subjects estimated sleep onset latency (in minute),
number of awakenings, time awake before rising (in minute),
and total sleep time (in minute).
Subjective evaluations of mood, sedation, and driving
quality were assessed using a series of visual analogue scales
(100 mm). The subjects were instructed to rate their subjective
feelings using a 16-item mood scale which provides three-
factor analytically defined summary scores for “alertness,”
“contentedness,” and “calmness” (Bond 1974).
Subjective feelings of sleepiness were rated with the
Karolinska Sleepiness Scale (Akerstedt and Gillberg 1990),
ranging from 1 (extremely alert) to 9 (very sleepy, fighting
sleep).
Subjects rated the degree of mental effort they had to put in
driving performance with the Rating Scale Mental Effort
(Zijlstra 1993). The scale is a visual analogue scale
(150 mm) with additional verbal labels.
The driving instructors rated each subject’s driving quality
and apparent sedation at the conclusion of the Highway
Driving Test, using two 100 mm visual analogue scales rang-
ing from “very bad” to “very good,” and from “not at all” to
“completely,” respectively.
Procedure
All subjects completed two nights of sleep evaluation and
testing. The first night was a habituation and practice condi-
tion to familiarize the subjects with the sleeping facilities and
polysomnographic and test procedures. The second night was
for actual sleep and performance assessments. Within 10 days
before their habituation night, the subjects were individually
trained to perform the cognitive and psychomotor tests during
two sessions of approximately 1.5 h.
A test condition started in the evening of day 1, when the
subjects arrived at the site at approximately 1900 hours, and
lasted until day 2, when they were discharged at approximate-
ly 114 hours. On arrival at the sleeping facility, the subjects
rated their subjective feelings and subjective sleepiness. From
1930 until 2030 hours, they performed the first session of
laboratory tests, comprising the Word Learning Test immedi-
ate and first delayed recall, the Critical Tracking Task, the
Divided Attention Task, the Psychomotor Vigilance Task, the
Stop Signal Task, and the Digit Span forward and backward.
Hereafter, electrodes for polysomnographic recording were
attached and subjects retired to bed at 2330 hours.
Immediately preceding retiring, the subjects in the “frequent
users” group ingested their own prescribed hypnotic, whereas
the subjects in the “infrequent users” group and controls did
not ingest medication.
The subjects were awakened at 0730 hours, and after
arising, a light standardized breakfast was served. At 0800
hours, the subjects evaluated sleep quality and duration, and
feelings of daytime sleepiness and alertness. Subsequently,
they started the second session of laboratory tests, comprising
the second delayed recall and word recognition parts of the
Word Learning Test, the Critical Tracking Task, the Divided
Attention Task, the Psychomotor Vigilance Task, and the
Digit Span test. At 0900 hours, the subjects were transported
to the Highway Driving Test which they performed between
0930 and 1030 hours. Upon completion, the subjects rated the
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mental effort it took to perform this driving test, and continued
to perform a Car-Following Test. After this, the subjects
returned to the testing facilities for removal of the electrodes
and were discharged.
During participation, use of caffeine was prohibited from
8 h prior to arrival on test days, until discharge the next
morning. Alcohol intake was not allowed from 24 h prior to
each dosing until discharge. Smoking was prohibited from 1 h
prior to bedtime until discharge.
Statistical analysis
The primary parameter of the study was the SDLP (in
centimeter). All performance-related parameters were
analyzed for group differences at separate time points
(evening, morning) using analysis of covariance
(ANCOVA) with participant’s sex, age, and years of
education as covariates. Significant (p < 0.05) main
effects of group were further analyzed using three
pairwise comparisons with LSD adjustment for multiple
comparisons. Sleep parameters were analyzed for group
differences using analysis of variance (ANOVA) with
Welch test for unequal variances. Significant (p <
0.05) main effects of group were further analyzed using
three pairwise comparisons with LSD adjustment for
multiple comparisons. A natural log transformation was
used before analysis of highly skewed variables.
Tables show means and standard deviations of variances
untransformed scores.
All statistical analyses were done by using the Statistical
Package for the Social Sciences (SPSS) statistical program
(version 21.0.0.1 for Windows; SPSS, Chicago, IL).
Results
Group differences for the screening variables
A total of 63 subjects (34 men, 29 women) completed
the study. They had a mean (±SD) age of 61.6 (±5.1)
years and an average education of 12 (±3) years. They
had their driving license on average for 39 (±8) years
and drove on average 9,965 (±7,848) km per year over
the last 3 years. There were no significant differences
between the three groups (Table 1).
Evaluation of sleep at home differed significantly
between groups. As shown in Table 1, sleep quality
was poorer in both insomnia groups as compared to
controls, as indicated by significantly higher scores on
the PSQI, GSQS-general, and the sleep subscale of the
SCL90-R (p < 0.001). There were no differences in
mean PSQI, GSQS, and SCL90-R sleep scores between
the insomnia groups. Scores on the SWEL showed that
sleep complaints were most frequently classified by
patients as sleep initiation and sleep maintenance prob-
lems, and occasionally as early morning awakenings,
with similar prevalences in frequent and infrequent
users. None of the controls reported problems with
sleep onset, sleep maintenance, or early awakening.
Both insomnia groups scored significantly higher than
controls on rating scales of depression (BDI p < 0.001;
SCL90-R p < 0.004), without significant differences be-
tween the frequent and infrequent users. Anxiety was also
increased in insomniacs as compared to controls, as shown
by significantly higher scores on both subscales of the STAI
in both groups (STAI state: frequent users p = 0.044 and
infrequent users p < 0.001; STAI trait: frequent users p =
0.005 and infrequent users p < 0.001). A significant differ-
ence on the SCL90-R anxiety scale was found between the
infrequent users and controls (p = 0.006), but not between
the frequent users and controls. There were no significant
differences in anxiety ratings between the insomnia groups.
The Multidimensional Fatigue Inventory showed sig-
nificant differences between groups on all five sub-
scales. Both insomnia groups reported suffering from
significantly more general fatigue (both p < 0.001),
physical fatigue (both p < 0.001), and more mental
fatigue (frequent users p < 0.001 and infrequent users
p = 0.002) when compared to the control group. In
addition, both groups reported significant reductions in
motivation (frequent users p = 0.015 and infrequent
users p = 0.027), and frequent users also reported re-
duced activity (p = 0.040). No differences between the
insomnia groups were found on any of the scales.
Sleep diary
The 2-week sleep diary showed that complaints of dis-
turbed sleep as measured by the GSQS-specific were
significantly increased in both insomnia groups as com-
pared to controls (Table 2). Compared with the healthy,
good sleepers, the infrequent users group reported sig-
nificantly more sleep complaints (p < 0.001), longer
sleep onset time (p < 0.01), shorter total sleep time
(p < 0.001), reduced sleep efficiency (p < 0.001), earlier
morning awakenings (p < 0.05), and more awakenings
(p < 0.001). Sleep quality in the frequent users group
was significantly worse as compared to the good
sleepers in number of sleep complaints (p < 0.001),
sleep onset time (p < 0.01), and sleep efficiency
(p < 0.01). Comparisons between the two insomnia
groups revealed that the infrequent users reported a
shorter total sleep time (p < 0.01), the lower sleep
efficiency (p < 0.01), and more awakenings (p < 0.05)
than the frequent users showing that sleep was worst in
infrequent user group.
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Hypnotic use
The hypnotics used in the frequent users group were
zopiclone (n = 4), temazepam (n = 4), midazolam
(n = 4), oxazepam (n = 3), zolpidem (n = 2),
lormetazepam (n = 2), clonazepam (n = 1), flurazepam
(n = 1), and nitrazepam (n = 1). Their average (±SD)
duration of hypnotic use was 7.7 (6.8) years. The aver-
age (±SD) nightly use of the hypnotics was 6.4 (1.2)
nights a week (Table 3).










Sex (M:F) 11:11 10:10 13:8
Age (years) 62.1 (4.4) 60.8 (5.9) 61.7 (5.0) 0.40
Education (years) 12.3 (3.3) 10.9 (2.7) 13.2 (3.3) 2.67
Average annual mileage (km) 8,525 (6,269) 11,875 (11,534) 9,655 (4,157) 0.98
Driving license (years) 38.0 (8.3) 39.0 (8.4) 40.6 (5.9) 0.64
Sleep
Pittsburgh Sleep Quality Index 12.6 (3.5)a 12.6 (2.6)a 2.4 (1.6) 100.2***
Groningen Subjective Quality of Sleep-general 9.4 (3.0)a 11.1 (1.7)a,b 1.0 (1.5) 126.1***
Sleep Wake Experience Listc
Sleep initiation problems 12a 10a 0 17.0***
Sleep maintenance problems 14a 13a 0 23.6***
Early morning awakenings 7a 5a 0 7.73*
Difficulty waking up 2 2 0 2.15
Tiredness upon waking up 3 2 0 2.91
Daytime sleepiness 5 3 1 2.84
Psychological
Symptom Checklist 90-R
Sleeping problems 9.6 (3.1)a 10.0 (2.5)a 3.3 (0.7) 52.6***
Depression 26.7 (9.7)a 27.1 (10.7)a 18.0 (3.0) 7.62***
Anxiety 15.8 (7.3)a 13.9 (4.8) 10.8 (1.3) 5.28**
Phobic anxiety 8.9 (4.5) 7.4 (1.0) 7.3 (0.8) 2.42
Psychoneuroticism 141.9 (37.1)a 137.9 (39.6)a 103.0 (13.1) 9.37***
Somatization 20.5 (7.9)a 19.1 (5.9)a 14.2 (1.8) 6.80**
Cognitive insufficiency 16.1 (6.3)a 15.8 (8.1)a 11.0 (1.8) 4.78*
Interpersonal sensitivity 25.8 (6.5) 24.8 (8.4) 21.7 (5.6) 2.11
Hostility 7.4 (1.6) 7.9 (2.8) 6.8 (1.3) 1.41
Beck Depression Inventory 8.6 (5.0)a 8.6 (6.6)a 2.8 (3.0) 9.38***
State-Trait Anxiety Inventory
State anxiety 35.3 (10.1)a 41.9 (10.8)a 27.1 (6.2) 10.03***
Trait anxiety 38.4 (10.9)a 41.4 (12.8)a 27.2 (5.7) 9.30***
Multidimensional Fatigue Inventory
General fatigue 11.8 (3.7)a 11.9 (3.7)a 6.8 (2.5) 16.4***
Physical fatigue 10.9 (3.5)a 10.6 (3.5)a 6.6 (2.3) 12.2***
Mental fatigue 11.5 (3.9)a 10.8 (3.5)a 7.0 (2.4) 11.2***
Reduced motivation 9.8 (3.6)a 9.6 (4.2)a 6.7 (2.5) 5.29**
Reduced activity 10.1 (4.2)a 10.0 (3.2) 7.4 (2.6) 4.03*
* p<0.05; ** p<0.01; *** p<0.001
a Significant difference with control group (p<0.05; post hoc analysis with Bonferroni correction)
b Significant difference between frequent and in frequent users (p<0.05; post hoc analysis with Bonferroni correction)
c Values for each variable are the frequencies in each group, and statistics represents results of Chi-square test
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Within the infrequent users group, seven patients re-
ported no history of hypnotic use. The remaining 13
patients used hypnotics infrequently and irregularly. Their
average (±SD) nightly use was 4.1 (2.9) nights a month
Table 2 Sleep diary
Main effect of Groupa
Variable Frequent users Infrequent users Controls F p
Groningen Subjective Quality of Sleep scale 6.0 (2.6)b 6.8 (2.0)b 1.9 (1.1) 56.40 <0.001
Time in bed (min) 521 (61) 499 (53) 495 (37) 1.37 0.267
Total sleep time (min) 411 (73) 349 (71)b, c 440 (37) 12.53 <0.001
Sleep efficiency (%) 79 (13)b 69 (12)b, c 89 (7) 21.87 <0.001
Sleep onset time (min) 43 (37)b 44 (30)b 17 (18) 7.96 0.001
Number of awakenings 0.8 (0.7) 1.4 (0.9)b, c 0.5 (0.4) 7.77 0.002
Early morning awakening (min) 33 (43) 50 (42)b 18 (14) 5.85 0.007
aUsing the Welch test of one-way ANOVA
b Significant difference with control group (p<0.05; post hoc analysis with LSD correction)
c Significant difference between frequent and in frequent users (p<0.05; post hoc analysis with LSD correction)
Table 3 Overview of individual hypnotic use and their pharmacokinetic properties. Hypnotics are listed in increasing order of expected residual effects
Hypnotic Dose (mg) t1/2 (hours)
a Residual effects








Zolpidem 10 1.9±0.2 I (unlikely) 12.5 3 4 Female 58
Zolpidem 10 1.9±0.2 I (unlikely) 15.6 10 7 Male 59
Midazolam 7.5 1.9±0.6 I (unlikely) 13.2 1.5 7 Male 68
Midazolam 7.5 1.9±0.6 I (unlikely) 16.8 5 7 Male 64
Midazolam 7.5 1.9±0.6 I (unlikely) 16.3 4 7 Male 64
Midazolam 7.5 1.9±0.6 I (unlikely) 19.9 3 7 Female 57
Lormetazepam 0.5 10±2.5 I (unlikely) 20.4 7 6 Male 55
Temazepam 10 11 I (unlikely) 14.7 30 4 Female 63
Temazepam 10 11 I (unlikely) 27.6 4 4 Male 65
Temazepam 10 11 I (unlikely) 24.0 15 7 Female 69
Temazepam 20 11 I (unlikely) 13.3 1.5 7 Female 56
Zopiclone 3.75 5 I (unlikely) 12.3 3 7 Female 58
Zopiclone 3.75 5 I (unlikely) 12.8 15 7 Female 63
Zopiclone 3.75 5 I (unlikely) 18.9 2 7 Female 60
Nitrazepam 5 26±3 II (minor) 21.6 12 7 Female 68
Zopiclone 7.5 5 II (moderate) 17.0 13 7 Male 61
Oxazepam 10 8±2.4 NA 16.5 1.5 7 Male 68
Oxazepam 20 8±2.4 NA 15.4 9 7 Male 62
Oxazepam 50 8±2.4 II (moderate) 25.2 1 7 Male 63
Lormetazepam 2 10±2.5 II (moderate) 16.0 10 4 Male 63
Flurazepam 15 1–2 (74±24)c II (moderate) 14.1 11 7 Female 56
Clonazepam 0.5 19–60 NA 18.5 7 7 Female 67
a Information derived from Vermeeren (2004), information about clonazepam derived from (Riss et al. 2008)
b Hypnotics’ residual effects are categorized according to a calibration scheme in which the impairment of a hypnotic is compared with blood alcohol
concentrations (BAC). Category I = unlikely to produce an effect, equivalent to BAC <0.2 g/L; category II = likely to produce minor or moderate effects,
equivalent to BAC 0.2–0.5 g/L; category III = likely to produce severe effects, equivalent to BAC >0.5 g/L (Wolschrijn et al. 1991; De Gier et al. 2009);
NA = information not available
c Half-life of active metabolite between brackets
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and with an average (±SD) duration of hypnotic use of 7.8
(7.9) years. The hypnotics used were temazepam (n = 6),
zopiclone (n = 4), lorazepam (n = 1), loprazolam (n = 1),
and nitrazepam (n = 1).
Sleep the night before driving
Table 4 presents the sleep parameters of the objective
and subjective sleep evaluation for each group.
Polysomnography showed no differences between the
three groups on any of the parameters measured. In
contrast, significant overall group differences were
found for subjective evaluations of total sleep time
(p = 0.005), sleep onset time, and sleep quality
(p = 0.001). Both insomnia groups reported significant-
ly more sleep complaints on the GSQS than the control
group (p values <0.01). In addition, the infrequent users
group reported significantly shorter total sleep times
(p < 0.01) and longer sleep onset times (p < 0.05) than
the control group. The frequent users group did not
differ from the control group.
Driving, cognitive, and psychomotor performance
Figure 1 and Table 5 show the driving performance
parameters. The primary performance parameter, SDLP
in the highway driving test, was on average normal and
similar for infrequent users (17.7 ± 2.9 cm), frequent
users (17.4 ± 4.3 cm), and controls (16.8 ± 2.7 cm)
(Fig. 1). Table 3 illustrates the hypnotics and doses used
by the frequent users and the corresponding SDLP
scores. Inspection of the average SDLP scores from
users of category I drugs and category II drugs shows
that performance in the category I group appears to be
better than the category II group. Mean (±SD) SDLP
scores are 16.8 (4.7) and 18.3 (3.5) cm, respectively.
The secondary driving task, the Car-Following Test, was
not different between the groups as well. All participants were
able to respond to the changes of the preceding car in a similar
fashion.
Finally, there were no significant differences in perfor-
mance on any of the psychomotor or cognitive tests. There
were tendencies (p < 0.10) towards group differences in the
divided attention test and the digit span test. For the digit span
Table 4 Mean (±SD) of objective and subjective sleep parameters
Main effect of Groupa
Variable Frequent users Infrequent users Controls F p
Total sleep time (minutes)
Polysomnography 383 (35) 389 (46) 408 (40) 2.34 0.107
Subjective evaluation 351 (101) 302 (94)b 395 (74) 6.21 0.005
Sleep onset time (minutes)
Polysomnography 26 (10) 19 (13) 19 (15) 2.83 0.071
Subjective evaluationc 27 (16) 68 (73)b, d 35 (37) 4.18 0.023
Number of awakenings
Polysomnography 7.9 (4.1) 10.2 (4.3) 7.5 (4.5) 2.33 0.111
Subjective evaluationc 2.1 (1.6) 3.0 (2.5) 1.9 (1.5) 0.99 0.382
Polysomnographic parameters
Sleep efficiency (%) 80 (9) 81 (9) 85 (8) 1.89 0.165
Wake after sleep onset (minutes) 77 (65) 73 (39) 55 (36) 1.53 0.229
Stage 1 sleep (% of total sleep time) 7 (3) 7 (2) 6 (3) 0.72 0.492
Stage 2 sleep (% of total sleep time) 57 (6) 55 (7) 56 (9) 0.66 0.522
Stage SWS sleep (% of total sleep time) 18 (9) 19 (6) 17 (6) 0.67 0.517
Stage REM sleep (% of total sleep time) 19 (4) 20 (6) 22 (6) 1.84 0.173
Subjective evaluation
Early morning awakening (minutes)c 51 (58) 67 (62) 28 (35) 2.52 0.093
Groningen Subjective Quality of Sleep scale 6.7 (3.9)b 7.8 (3.8)b 3.6 (3.2) 8.48 0.001
aUsing the Welch test of one-way ANOVA
b Significant difference with control group (p<0.05; post hoc analysis with LSD correction)
c Scores were transformed (ln) for statistical analysis to correct for skewness
d Significant difference between frequent and in frequent users (p<0.05; post hoc analysis with LSD correction)
Psychopharmacology (2014) 231:2851–2865 2859
test, this was mainly due to worse performance by frequent
users as compared to controls in the morning. In the divided
attention test, there was a tendency for group differences in the
tracking subtask, due to worse tracking performance by the
controls as compared to the both patient groups.
Comparisons between performance in the evening and
morning sessions showed significant differences in the reac-
tion times in the PVT and delayed recall in the word learning
test. The latter was as expected because the interval between
learning and delayed recall increased from evening tomorning
sessions. Average reaction time in the PVT was significantly
faster in the morning as compared to the evening in controls (p
< 0.005), but not in the insomnia groups.
Performance in the critical tracking test, divided attention
task, and the stop signal task showed no significant differences
between times of day (evening vs. morning).
Subjective rating scales
As shown in Table 6, patients felt on average less alert and
more sleepy than controls as measured by the mood rating
scale and the KSS, but this was only significant for alertness in
the evening (p = 0.002). In the evening, frequent users had
significantly lower alertness scores than controls.
Furthermore, all groups felt on average less alert and more
sleepy in the morning as compared to the evening. Pairwise
comparisons showed that these differences were only signif-
icant in the controls (p < 0.01), but not in the patients.
No group differences were found in the evaluation by the
instructors of the participants’ driving quality and apparent
sedation. In addition, although showing a marginal trend to
the detriment of the infrequent users, no differences between
the groups were found in subjectively rated mental effort the
participants needed to put in the driving test.
Discussion
The present study is the first directly comparing driving per-
formance between insomnia patients who chronically use hyp-
notics, insomnia patients who do not or infrequently use hyp-
notics, and healthy, good sleepers. Results show that driving,
as measured by a standardized highway driving test and a car-
following test, is not impaired in insomniacs, irrespective of
the use of hypnotics. In addition, the present study shows that
driving-related psychomotor and cognitive performance is not
different between pharmacologically treated insomnia patients,
untreated insomnia patients, and healthy, good sleepers.
Table 5 Mean (±SD) of driving performance parameters
Main effect of Groupa
Variable Frequent users Infrequent users Controls F p
Highway Driving Test
Standard deviation of lateral position (in cm) 17.4 (4.3) 17.7 (2.9) 16.8 (2.7) 0.74 0.484
Mean speed (in km/h) 94.5 (1.5) 93.9 (1.9) 94.3 (1.4) 0.60 0.555
Standard deviation of speed (in km/h) 2.11 (0.51) 2.34 (0.68) 2.18 (0.66) 1.01 0.371
Car-Following Test
Reaction time (in s) 3.55 (1.57) 3.32 (1.40) 3.06 (1.01) 0.10 0.906
Gain 1.14 (0.13) 1.21 (0.25) 1.15 (0.12) 0.46 0.637
Subjective Evaluation of Driving Test
Subjective driving quality 67 (11) 68 (10) 65 (14) 0.73 0.488
Apparent sedation 12 (11) 12 (15) 9 (10) 1.01 0.349
Mental effortb 30 (23) 36 (25) 20 (14) 2.52 0.090
aANCOVAwith sex, age, and education as covariates
b Scores were transformed (ln) for statistical analysis to correct for skewness
Fig. 1 Individual SDLP data for each group separately. Horizontal bars
indicate average SDLP
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Results of the study corroborate previous findings showing
an absence of neuropsychological deficits in both pharmaco-
logically treated and untreated insomniacs (Vignola et al.
2000). Aside from minor attentional problems in insomniacs,
that study reported no significant differences in performance
between treated insomniacs, untreated insomniacs, and
healthy, good sleepers. The authors suggested, however, that
the absence of cognitive impairment may have been due to
methodological limitations. The tests used in their study were
of short duration and demanded low effort (e.g., digit symbol
Table 6 Mean (±SD) of psychomotor and cognitive performance parameters
Main effect of Groupa
Variable Frequent users (n = 22) Infrequent users (n = 20) Controls (n = 21) F p
Critical Tracking Task
Average lambda (in rad/s), evening 3.34 (0.72) 3.23 (0.60) 3.03 (0.49) 2.39 0.101
Average lambda (in rad/s), morning 3.29 (0.70) 3.21 (0.72) 3.02 (0.49) 1.26 0.293
Divided Attention Task
Tracking subtask: average error (in mm), evening 14.1 (5.2) 14.4 (4.4) 17.4 (5.2) 2.45 0.095
Tracking subtask: average error (in mm), morning 15.5 (5.9)b 14.9 (4.2)b 18.7 (5.2) 2.87 0.065c
Detection subtask: reaction time (in ms), evening 1,924 (328) 1,974 (299) 1,973 (335) 0.70 0.501
Detection subtask: reaction time (in ms), morning 2,030 (344) 1,898 (288) 1,920 (338) 0.33 0.720
Stop Signal Task
Go reaction time (in ms) 423 (63) 427 (77) 422 (50) 0.98 0.907
Stop signal reaction time (in ms) 179 (35) 178 (31) 181 (35) 0.02 0.980
Psychomotor Vigilance Task
Median reaction time (in ms), evening 254 (34) 244 (31) 247 (23) 0.47 0.631
Median reaction time (in ms), morning 252 (35) 242 (30) 241 (21) 1.52 0.228
Lapses (>500 ms), evening 1.2 (2.0) 1.3 (1.1) 1.0 (1.3) 0.12 0.885
Lapses (>500 ms), morning 1.3 (2.1) 0.7 (1.0) 0.7 (1.2) 0.71 0.495
Word Learning Task
Immediate total recall score 46.3 (12.3) 46.8 (9.4) 49.4 (9.0) 0.35 0.707
Delayed recall score, evening 7.8 (3.5) 8.4 (2.9) 8.9 (3.4) 1.36 0.266
Delayed recall score, morning 6.5 (2.5) 7.0 (3.4) 7.3 (3.2) 0.72 0.491
Recognition score 24.8 (4.4) 24.6 (3.0) 25.7 (3.4) 0.30 0.746
Recognition reaction time (in ms) 924 (189) 892 (192) 883 (141) 0.14 0.868
Digit Span
Forward score, evening 3.6 (1.3) 3.8 (1.1) 3.9 (1.2) 0.37 0.693
Forward score, morning 3.5 (0.9)b 4.0 (1.1) 4.4 (1.1) 2.88 0.064c
Backward score, evening 3.5 (1.3) 3.9 (1.4) 4.3 (1.1) 1.61 0.209
Backward score, morning 3.3 (1.0)b 3.8 (1.4) 4.2 (1.1) 2.66 0.079c
Subjective Evaluations of Feelings
Alertness, evening 66 (17)*, b 74 (13) 81 (13) 6.80 0.002c
Alertness, morning 64 (19) 69 (14) 74 (15) 2.86 0.066
Contentedness, evening 73 (21) 78 (13) 83 (13) 2.19 0.122
Contentedness, morning 75 (19) 76 (12) 81 (14) 1.02 0.368
Calmness, evening 70 (23) 75 (14) 82 (14) 2.64 0.081
Calmness, morning 73 (17) 73 (14) 80 (14) 0.93 0.401
Karolinska Sleepiness Scale, evening 3.91 (1.66)b 3.90 (1.65)b 3.00 (0.84) 2.90 0.063c
Karolinska Sleepiness Scale, morning 4.55 (1.50) 4.30 (1.72) 3.81 (1.25) 1.86 0.165
* p<0.05, significant difference from control group using pairwise comparisons of ANCOVA
aANCOVAwith sex, age, and education as covariates; ;
b Significant difference with control group (p<0.05; post hoc analysis with LSD correction)
c Significant (p<0.05) main effect of group using the Welch test of one-way ANOVA
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substitution test and purdue pegboard test). Consequently,
insomnia patients may have been able to exert enough effort
for a short period to complete the tests successfully.
In the present study, subjects performed a standardized
highway driving test for approximately 1 h. The prolonged
attentional demands of the task were expected to reveal pos-
sible performance deficits in insomnia patients, which were
not found with tasks of short duration. Yet, there were no
indications of deterioration in driving performance in insom-
nia patients, irrespective of use of hypnotics.
These results can be interpreted in two ways. First, sleep in
the insomnia groups was undisturbed according to polysom-
nographic criteria leaving daytime performance unaffected.
Despite significantly more subjective sleep complaints report-
ed by the insomniacs when compared with the healthy, good
sleepers, there was no objective evidence for any sleeping
problems. Polysomnographic data showed that there were no
differences between the groups on any of the sleep parameters
obtained from the laboratory recordings. Discrepancies be-
tween subjective and objective sleep parameters have been
established in previous studies (e.g., Orff et al. 2007; Vignola
et al. 2000). A limitation in those studies was that participants’
sleep was only assessed during one night, possibly causing
“first night effects” in healthy, good sleepers and “reversed
first night effects” in insomnia patients. The present study,
therefore, used the recommended second night recordings for
determination of objective sleep complaints. Yet, there were
no indications of any objective evidence for sleeping difficul-
ties. It is suggested, however, that the current standards of
sleep analysis may not have sufficient sensitivity for
distinguishing insomnia from healthy, undisturbed sleep
(Bastien et al. 2003). A possible solution can be found in
spectral analysis of the sleepmicrostructure, dissociating char-
acteristic electroencephalographic activities. More research is
needed to confirm this presumption.
The lack of objectively measured sleep complaints may be
also due to the sleeping environment. It has been shown that
home-based polysomnographic recordings yield different re-
sults than recordings at the laboratory (Edinger et al. 1997).
Insomnia patients’ sleep appears more disturbed when they
sleep at home than when they sleep at the laboratory. Indeed,
subjective sleep evaluations in the present study show that
sleep quality at the laboratory improved in both insomnia
groups. In addition, subjective sleep quality for the healthy
controls was worse after laboratory sleep than after sleep at
home. Sleep quality changed even close to insomnia levels on
some of the parameters. These changes in sleep quality may
have resulted in a less pronounced difference between the
groups and may have minimized existing differences in ob-
jective sleep recordings. Additionally, the changed sleep qual-
ity may have had an influence on daytime performance, i.e.,
improved in patients due to improved sleep and impaired in
healthy controls due to impaired sleep. Improved daytime
functioning as a result of improved sleep in insomnia patients
has been shown previously (Edinger et al. 2003). In contrast,
healthy good sleepers, in particular elderly, do not seem to
suffer greatly from a single night of disturbed sleep (Philip
et al. 2004). Still, it remains to be investigated whether sleep at
home would influence driving performance differently than
sleep at the laboratory in both insomnia patients and good
sleepers.
A second explanation for the absence of impairment in
driving performance may be that the insomnia patients, who
had ample driving experience, may have been easily able to
complete the driving tests successfully. In a recent study, it has
been shown that establishing performance impairment in in-
somnia may be dependent on task complexity (Altena et al.
2008). Insomnia patients performed worse than healthy con-
trols only in a complex vigilance task, whereas the patients’
performance in a simple reaction time task appeared to be
even better than healthy controls. The authors concluded that
chronic insomnia is associated with cognitive dysregulation,
but that this may only be revealed in tasks measuring higher
level functioning. Driving is a well-practiced and highly au-
tomated skill (Brouwer 2002) and may not require such high
demands on cognitive functioning. Judging from the low
values scored on the mental effort scale, this assumption
seems to be confirmed. Scores on the scale can range from 0
to 150. The average scores in the present study were 30.3 for
the medicated insomnia patients, 35.7 for the unmedicated
insomnia patients, and 20.3 for the healthy controls. In a study
comparing cognitive performance between patients with sea-
sonal allergic rhinitis and healthy controls, subjects evaluated
the mental effort they had to put in a 45-min sustained atten-
tion test considerably higher (Hartgerink-Lutgens et al. 2009).
Mental effort scores were around 90 for both groups, indicat-
ing substantial higher demands of that test as compared with
the highway driving test.
Yet, the insomniacs, in particular the infrequent users
group, evaluated the degree of mental effort they had to put
in the driving test tentatively higher than the healthy controls.
Although not reaching statistical significance, this may sug-
gests that the insomnia patients masked possible performance
difficulties by increasing their effort. As mentioned earlier, the
short duration of cognitive tasks was considered to be a
limitation for revealing any performance deficits in insomnia
patients. It seems that even tasks with duration of at least 1 h
can be completed successfully by individuals reporting
sleeping difficulties.
In addition to the findings that driving is not affected in
insomnia patients, results of the present study show that
driving is not impaired in patients chronically using hypnotics
as well. The absence of impairment, combined with the still
present subjective sleep complaints, suggests the development
of tolerance to both therapeutic and residual effects of hyp-
notics. With respect to the residual effects, the results are
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partly supported by epidemiological data (Neutel 1998).
These showed that prolonged use of hypnotics is associated
with a lowered risk of becoming involved in a car accident
when compared with initial use of hypnotics. Nevertheless,
the risk of injurious traffic accidents after chronic use of
hypnotics remained twice as high in long-term hypnotic users
in comparison to healthy, unmedicated drivers.
The absence of residual effects in the present study may be
explained by the wide variety of hypnotic drugs and doses
used in the frequent users group, however. In addition, the
majority of hypnotics were unlikely to produce residual ef-
fects between 10 to 11 h post dose. Consequently, the large
differences in degree of residual effects may have contributed
to the variability of performance in this group and masked any
detectable impairment. This is supported by the inspection of
the average SDLP scores from the category I and the category
II users, showing that the former group had a slightly lower
average SDLP score (16.8 cm) than the latter (18.3 cm).
Comparing these values with two studies investigating the
residual effects of zopiclone 7.5 mg in younger (Leufkens
et al. 2009) and older (Leufkens and Vermeeren 2009) healthy,
medication naïve, participants reveals that performance was in
the range of driving after administration of placebo. Both age
groups had placebo SDLP scores of 17.8 cm (95% confidence
interval 16.8–18.2 cm). Future research in patients chronically
using the same hypnotic is needed to shed more light on this
issue. The present study aimed, however, to evaluate driving
performance in a representative, non-selective study sample of
insomnia patients chronically using hypnotics.
The results may differ when driving is investigated in a
younger sample of insomniacs. A recent review showed that
the residual effect of zopiclone on driving in older subjects
(age ranging from 56 to 73) was generally less than that found
in younger subjects (age ranging from 21 to 45 years)
(Leufkens and Vermeeren 2013). An explanation for this
effect may be found in age-related increases in driving expe-
rience. The driving-related skills of less experienced drivers
may be more sensitive to drug-induced sedation.
Consequently, driving performance could be impaired to a
larger extent by hypnotic use in younger insomnia patients
than in older patients.
It may be argued that the driving tests are not sensitive enough
to detect performance deficits as a consequence of a disorder.
Studies assessing driving performance in other patient groups
using the same standardized driving test have been conducted
previously. Direct comparisons with healthy controls have been
reported for patients with chronic nonmalignant pain
(Veldhuijzen et al. 2006) and depressed patients receiving long-
term antidepressant treatment (Wingen et al. 2006). In contrast to
the present study, these studies showed that driving was signif-
icantly impaired in both patient groups as compared with healthy
controls. These results suggest that the driving test has sufficient
sensitivity for detecting driving impairment in patient groups. In
addition, sample sizes of the previous studies were similar to the
present study, suggesting that the absence of effects of insomnia
could not be explained in terms of statistical power.
Finally, it may be questioned whether the study had sufficient
power to detect differences in driving performance between
insomnia patients and controls. We do not believe this is the
case. First of all, the mean difference in SDLP between infre-
quent users and controls was small (i.e., less than 1 cm), and not
considered clinically relevant. The minimum clinically relevant
difference in SDLP is 2.4 cm which corresponds to the effect of
alcohol when blood alcohol concentrations are at the legal limit
for driving in most countries. Secondly, previous studies
assessing driving performance in other patients groups, using
the same standardized driving test, have shown that the method
is sufficiently sensitive to detect significant impairment in small
samples of patients with chronic nonmalignant pain (Veldhuijzen
et al. 2006) and depressed patients receiving long-term antide-
pressant treatment (Wingen et al. 2006). It seems therefore that
the effects of insomnia and chronic use of hypnotics are relatively
small and less debilitating than the effects of pain and depression.
To conclude, results of the present study indicate that
driving performance is not substantially impaired in older
chronic users of hypnotics and older insomnia patients who
do not use hypnotics. This supports conclusions from previous
studies that effects of insomnia and chronic use of hypnotics
on cognitive performance are subtle.
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